---

$3.40

+0.0400 ( +1.19% ) 125.3K

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-08-13	Sale	-125000.00	To Lucy
2024-07-17	Sale	-20000.00	SKYLER JAY S
2024-07-17	Sale	-20000.00	Link David Charles
2024-07-17	Sale	-20000.00	Spragens Jeffrey G
2024-07-17	Sale	-20000.00	Polvino William James
2024-07-17	Sale	-46528.00	Sullivan Eddie Joe
2024-07-17	Sale	-20000.00	Lucera Erick
2024-07-17	Sale	-20000.00	HAMILTON CHRISTINE E
2024-07-17	Sale	-20000.00	Giberson Scott
2024-07-17	Sale	-35700.00	Reich Samuel J